Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Anticancer drug resistance: An update and perspective.

Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy - 1 Dec 2021

Nussinov Ruth, Tsai Chung-Jung, Jang Hyunbum

Abstract excerpt

Driver mutations promote initiation and progression of cancer. Pharmacological treatment can inhibit the action of the mutant protein; however, drug resistance almost invariably emerges. Multiple studies revealed that cancer drug resistance is based upon a plethora of distinct mechanisms. Drug resistance mutations can occur in the same protein or in different proteins; as well as in the same pathway or in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Artificial Intelligence

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Lung Neoplasms

Share to Mutation

Share to Piperazines

Share to Pyrimidines

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 34953682
DOI: 10.1016/j.drup.2021.100796
PMCID: PMC8810687

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Anticancer drug resistance: An update and perspective.PMID 34953682Read ↗

Direct K-Ras Inhibitors to Treat Cancers: Progress, New Insights, and Approaches to Treat Resistance.Semantic proximity Read ↗

Molecular Mechanisms of Cancer Drug Resistance: Emerging Biomarkers and Promising Targets to Overcome Tumor ProgressionSemantic proximity Read ↗

Genetic alterations shaping tumor response to anti-EGFR therapies.Semantic proximity Read ↗

Acquired Resistance to KRASG12C Inhibition in Cancer.Semantic proximity Read ↗

Identification of drug resistance mechanisms induced in response to KRAS therapeuticsSemantic proximity Read ↗

Emerging landscape of KRAS inhibitors in cancer treatment.Semantic proximity Read ↗

Genomic landscape of clinically acquired resistance alterations in patients treated with KRASG12C inhibitors.Semantic proximity Read ↗

More to the RAS Story: KRASG12C Inhibition, Resistance Mechanisms, and Moving Beyond KRASG12C.Semantic proximity Read ↗

KRAS-Targeted Therapies in NSCLC: Resistance, Combination Strategies, and Emerging Clinical Paradigms.Semantic proximity Read ↗

Resistance looms for KRAS G12C inhibitors and rational tackling strategies.Semantic proximity Read ↗

The evolving landscape of KRAS-targeted therapy: mechanisms of resistance and emerging strategies.Semantic proximity Read ↗

KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.